Cerus (CERS) Margin of Safety % (DCF Earnings Based): N/A (As of Aug. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CERS Cerus Corp CERS
78 GF Score
Price $2.74
GF Value $2.23
Valuation Modestly Overvalued
! 3 Warning Signs
View Full Analysis

What is Cerus Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

As of today (2026-08-27), Cerus's Predictability Rank is 3.5-Stars. Cerus's intrinsic value calculated from the Discounted Earnings model is $-0.85 and current share price is $2.74. Consequently,

Cerus's Margin of Safety % (DCF Earnings Based) using Discounted Earnings model is N/A.

CERS vs CTKB, TCMD, CBLL: Margin of Safety % (DCF Earnings Based) Comparison

For the Medical Devices subindustry, Cerus's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cerus Margin of Safety % (DCF Earnings Based) vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cerus's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Cerus's Margin of Safety % (DCF Earnings Based) falls into.


CERS
78GF Score
Cerus Corp CERS
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cerus Margin of Safety % (DCF Earnings Based) Calculation

Cerus's Margin of Safety % (DCF Earnings Based) for today is calculated as

Margin of Safety % (DCF Earnings Based)=(Intrinsic Value: DCF (Earnings Based)-Current Price)/Intrinsic Value: DCF (Earnings Based)
=(-0.85-2.74)/-0.85
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The intrinsic value is calculated from the Discounted Earnings model with default parameters. The calculation method is the same as Discounted Cash Flow model except earnings are used in the calculation instead of free cash flow.

Is Cerus (CERS) Overvalued in 2026?

Based on GuruFocus' analysis, Cerus stock appears to be overvalued. The current stock price of $2.74 is trading 22.9% above its estimated GF Value™ of $2.23. GuruFocus considers Cerus to be Modestly Overvalued.

Key valuation signals for CERS:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: $2.23 vs. price of $2.74 (22.9% above fair value)
  • GF Score™: 78/100 with 3 warning signs

No single metric tells the full story. See the CERS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cerus Business Description

Other Exchanges CU2:Germany
Address 1220 Concord Avenue, Suite 600, Concord, CA, USA, 94520
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.
78GF Score

Get the complete analysis for CERS

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.74
Price
$2.23
GF Value